People with Friedreich ataxia may develop lower urinary tract symptoms (LUTS), including overactive bladder and urinary storage difficulties. This clinical scenario requires a structured management approach, with treatment options specific to this population.
This protocol addresses individuals with Friedreich ataxia who present with lower urinary tract symptoms — specifically overactive bladder and urinary storage symptoms. Clinical evidence supports consideration of pharmacological therapy in this setting; antimuscarinic medications are among the evaluated options for managing storage symptoms in this population.
DOI: 10.1186/s13023-022-02568-3
We conditionally recommend consideration of a trial of antimuscarinic agents in individuals with Friedreich ataxia with LUT symptoms reporting urinary storage symptoms
Antimuscarinic medications may be considered for people with Friedreich ataxia displaying overactive bladder symptoms
Intradetrusor injections of botulinum toxin A or suprapubic catheterization may be considered as alternative intervention
View source ↗